Another trial [26] administered bevaziumab, a VEGF inhibitor, erlotinib, an EGFR inhibitor, and irinotecan, a topoisomerase I inhibitor among progressive DIPG patients. Here, EGFR is linked to diffuse intrinsic pontine glioma.